Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Dec 18 2009

Celgene Corporation (Nasdaq:CELG) today announced the National Cancer Institute (NCI), a part of the National Institutes of Health, reported initial data from a Phase III, randomized, double-blind, multi-center clinical study led by the Cancer and Leukemia Group B (CALGB). The investigational study evaluated REVLIMID^® compared to placebo in multiple myeloma patients following autologous stem cell transplant, and the independent Data and Safety Monitoring Board reported that the trial had met its primary endpoint of a statistically significant improvement in time to disease progression. The study was sponsored by the NCI under a Clinical Trials Agreement with Celgene.

Further results from the study will be presented in a peer-reviewed setting in 2010.